Navigation Links
Sanofi Withdraws Anti-obesity Drug in US

French pharmaceutical group Sanofi-Aventis said Friday it had withdrawn an application for regulatory approval for its anti-obesity drug Acomplia in the United States.

A panel of experts from the US Food and Drug Administration concluded earlier this month that the dieting treatment, referred to as rimonabant by the company, was unsafe and should not be sold in the United States.

"Sanofi-Aventis will work towards submitting the rimonabant file to the FDA at a future date," the company said, adding that it will "undertake the necessary discussions with the FDA to determine the required modifications to its file."

The FDA's expert panel concluded that suicidal thoughts appeared to be a side-effect of taking Acomplia, which has been authorised in the European Union.

The FDA was expected to heed the opinion of the panel of experts and block the sale of the drug.

Sanofi had previously forecast annual sales of 3.0 billion euros (4.0 billion dollars) for the drug.

In a separate development, European regulators said they were reviewing data on the psychiatric effects of Acomplia.

The European Medicines Agency (EMEA) said it expected to announce its conclusions at the end of a July 16-19 meeting.

The agency "is currently reviewing the available data on psychiatric events (in particular suicidal ideation and depression-related events)," it said.

Acomplia has been authorised in 37 countries and is currently sold in 18.


'"/>




Page: 1

Related medicine news :

1. FDA Gives Green Signal To Sanofi-Aventis SAs Cancer Drug Taxotere
2. Sanofi-Aventis sets the ball rolling for trials of H7N1 bird flu vaccine
3. Diabetes II May Be Controlled By Sanofis New Obesity Pill
4. Sanofi-Aventis Allows Thais To Make Plavix
5. Bayer Voluntarily Withdraws BAYCOL - A Drug Associated With 50 Deaths
6. Hospital Withdraws McDonalds Reward Scheme
7. Beef Firm in US Withdraws Its Products from Markets After E. Coli Outbreak.
8. Anti-obesity drugs for FDA approval
9. Canada Confronts Obesity Head-on, Anti-obesity Campaign on Fast Track
10. Anti-obesity Drugs Claimed Additional Benefits on cardiometabolic Risk Factors Questioned

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Sanofi Withdraws Anti obesity Drug

(Date:11/8/2009)... , WASHINGTON, Nov. 8 /PRNewswire-USNewswire/...merica (PhRMA) Senior Vice President Ken Johnson r...e health care reform bill: ,, "We are disappoin...iness echoed by millions of hardworking Americans ...House of Representatives who voted against the bil...
(Date:11/8/2009)... , Health Care Vote Shows Who Sides With Wor...SBURG, Pa., Nov. 8 On t...se of Representatives for a good, balanced health ...d its scoring of how our state,s U.S. representati...or America Act. ,, The legislation, which pass...
(Date:11/7/2009)... , WASHINGTON , Nov. 7 /PRNewswire-USNewswi...oor today in support of H.R. 3962, the Affordable ...on the legislation later tonight. Below are the S... we all know, is an historic moment for our nation... leaders of every party and political philosophy -...
(Date:11/7/2009)... , HOUSTON, Nov. 7 Calling th...sociation (AMA), the AMA President J. James Rohack...w physicians from all state and medical specialty ...policy-making meeting, where health system reform ...scom.com/cgi-bin/prnh/20081209/AMALOGO ) ,, "...
(Date:11/7/2009)... , WASHINGTON, Nov. 7 /PRNewswire-USNewswire/...he House of Representatives to vote for the Stupak..., "The Stupak-Ellsworth-Pitts-Kaptur-Dahlkemper-...t federal law on abortion funding and conscience p...ca Act (H.R. 3962)," they said. ,, The letter w...
Breaking Medicine News(10 mins):Health News:PhRMA Statement on House Passage of Health Care Reform Bill 2Health News:PhRMA Statement on House Passage of Health Care Reform Bill 3Health News:Robert Brady (D-PA-1), Chaka Fattah (D-PA-2), Kathy Dahlkemper (D-PA-3), Joe Sestak (D-PA-7), Patrick Murphy (D-PA-8), Christopher Carney (D-PA-10), John Murtha (D-PA-12), Paul Kanjorski (D-PA-11), Allyson Schwartz (D-PA-13), Mike Doyle (D-PA-14) Ge 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 2Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 3Health News:Pelosi: Health Legislation Founded on Key Principles for a Healthier America: Innovation, Competition and Prevention 4Health News:AMA President Kicks Off AMA Meeting Focused on Health Reform 2Health News:Bishops Urge Passage of Stupak-Ellsworth Anti-Abortion Amendment for Health Reform Bill 2
... A daily resource for people in searc...thritisToday.org is the new website by the Arthrit... Atlanta, GA (PRWEB) March 30, 2009 -- The Arthrit...aily lives of the 1 in 5 Americans living with art...
...lth, Qualcomm Join Forces as Founding Health Care ...h 30 Gary and Mary West Foundation today committe...nstitute, one of world,s first medical research or...h care affiliate, with Qualcomm as a founding spon...
...cial effects of anti-angiogenesis drugs in the tre...omas appear to result primarily from reduction of ...any direct anti-tumor effect, according to a study...e release, describes how treatment with the experi...
... New Patient Care Model Significantly Improves Pat...aVita Inc., a leading provider of kidney care serv...se (CKD), today released the findings of a study r...or new dialysis patients. The study presented at t...
...ho survive severe injuries on battlefields such as... developing infections of their wounds with multid...robes include superbugs such as methicillin resist...urray, from Brooke Army Medical Center, USA, told ...
...c surgeons are able to repair complex heart defect... but that doesn,t necessarily mean a happy ending ...at quality of life and others, with the same condi...rt disease, including African-Americans and lower-...
Other Medicine News:Health News:Arthritis Treatments and Joint Pain Relief Ideas Featured on Newly Launched Arthritis Today Web Site 2Health News:Gary and Mary West Foundation Commits $45 Million to Create Wireless Health Institute 2Health News:Gary and Mary West Foundation Commits $45 Million to Create Wireless Health Institute 3Health News:Angiogenesis inhibitor improves brain tumor survival by reducing edema 2Health News:Angiogenesis inhibitor improves brain tumor survival by reducing edema 3Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 2Health News:DaVita's IMPACT Program Reduces Mortality for New Dialysis Patients 3Health News:Physicians mending broken hearts 2
(Date:11/6/2009)..., SARASOTA, Fla., Nov. 6 /PRNewswire-FirstCall/ ...nounced that it has signed a definitive agreement ...roprietary medical devices. The Verathon Board of...osing is subject to customary regulatory approvals...roval. The parties expect the closing to be compl...
(Date:11/6/2009)..., PRINCETON, N.J., Nov. 6 /PRNewswire-FirstCall/...DSCI), a provider of advanced wound care products,... results before market on Monday, November 16, 200...me day to discuss the results at 11:00 am EST. Int...ic) or (857) 350-1684 (international), with passco...
(Date:11/6/2009)..., LEXINGTON, Ky., Nov. 6 /PRNewswire-FirstCall/ ... Board: VHGI) confirmed today that the previously ... related assets to Wound Management Technologies, ...ard of Directors and shareholders of VHGI. ,,...he potential stock dividend, royalty stream and ca...
Breaking Medicine Technology:Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 2Roper Industries Announces Two Acquisitions to Enhance Growth in Medical and Toll & Traffic Businesses 3Derma Sciences Announces Date of Its Third Quarter 2009 Earnings Release and Conference Call 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 2OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 3OTCBB-VHGI Updates Shareholders on Status of Healthcare Asset Sale and Treasure Gulch Gold Mine Development Strategy 4CorVel Announces Revenues and Earnings 47873 1CorVel Announces Revenues and Earnings 47873 2CorVel Announces Revenues and Earnings 47873 3CorVel Announces Revenues and Earnings 47873 4CorVel Announces Revenues and Earnings 47873 5CorVel Announces Revenues and Earnings 47873 6Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 47872 1Leading Sperm Bank Expands Fertility Preservation Services to the Big Apple 47872 2DC Government Renews Certified Business Enterprise Classification to Language Interpretation and Translation Firm 47870 1DC Government Renews Certified Business Enterprise Classification to Language Interpretation and Translation Firm 47870 2DC Government Renews Certified Business Enterprise Classification to Language Interpretation and Translation Firm 47870 3
...gs of amylin/leptin synergy and translational Phas... Proceedings of the National Academy of S...O, May 5 Amylin Pharmaceuticals, Inc.,(Nasdaq: A... clinical study,evaluating various dosing combinat...one amylin, and recombinant human leptin (r-metHuL...
...d Improvement in Symptoms Both in the Short and Lo...INGTON, Del., May 5 AstraZeneca (NYSE:,AZN) today...iapine,fumarate) Extended-Release Tablets for the ...eneralized anxiety disorder (GAD) in adult patient...ay at the 161st Annual,Meeting of the American Psy...
Other Medicine Technology:Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 2Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 3Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 4Amylin Pharmaceuticals Initiates Phase 2B Dose-Ranging Clinical Study of Pramlintide/Metreleptin Combination Treatment in Obesity 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14
NephroMax High Pressure Nephrostomy Balloon Catheter (Kit)
...oon is used to dilate the musculofacscial tract an...uring a percutaneous procedure. The Ultraxx balloo...to the catheter shaft at the tip. This short tip p...to the surgical site, enhancing access to difficul...
Amplatz Renal Dilator Set
...e therapy stimulates the spincter and pelvic floor...axation. By use of DETRUSAM as a prophylactic step... avoided. After necessary bladder lifting DETRUSAM...esical Catheter and the first autoclavable vaginal...
Medicine Products: